Gastroenterology

Back to articles

Preventive therapy with high-dose PPI and aspirin in Barrett’s esophagus

KEY POINT

Long-term use of a high-dose proton-pump inhibitor (PPI) and aspirin in patients with Barrett’s esophagus had the most beneficial effect on reducing all-cause mortality, esophageal adenocarcinoma, or high-grade dysplasia, whichever occurred first, according to results of the AspECT trial published in Lancet.

SOURCES

Jankowski JAZ, et al. Esomeprazole and aspirin in Barret’s oesophagus (AspECT): A randomized factorial trial. Lancet. 2018;392(10145):400–8.

Hvid-Jensen F, et al. Should aspirin and PPIs be recommended for patients with Barrett’s oesophagus? Lancet. 2018;392(10145):362–4.